专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2465527A3 Educated NKT cells and their uses in the treatment of immune-related disorders. 审中-公开
公开(公告)号：EP2465527A3
公开(公告)日：2012-09-12
申请号：EP11152810.5
申请日：2004-09-20
申请人： Enzo Therapeutics, Inc. a fully owned subsidiary of Enzo Biochem, Inc.
发明人： Ilan, Yaron , Margalit, Maya , Elinav, Eran
IPC分类号： A61K39/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/515 , C07K16/28 , C12N5/0636
摘要： The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell. The invention further provides for an ex vivo educated NKT cell and uses thereof in the treatment of immune-related or immune-mediated disorders.

2. 发明公开

EP2465529A3 Educated NKT cells and their uses in the treatment of immune-related disorders. 审中-公开
公开(公告)号：EP2465529A3
公开(公告)日：2012-09-05
申请号：EP11152812.1
申请日：2004-09-20
申请人： Enzo Therapeutics, Inc. a fully owned subsidiary of Enzo Biochem, Inc.
发明人： Ilan, Yaron , Margalit, Maya , Elinav, Eran
IPC分类号： A61K39/00 , A61K39/395 , C12N5/0783 , A61K35/12 , A61K35/407
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/515 , C07K16/28 , C12N5/0636
摘要： The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell. The invention further provides for an ex vivo educated NKT cell and uses thereof in the treatment of immune-related or immune-mediated disorders.

3. 发明公开

EP2465525A2 Educated NKT cells and their uses in the treatment of immune-related disorders. 审中-公开
标题翻译：形成NKT细胞及其在免疫相关疾病的治疗
公开(公告)号：EP2465525A2
公开(公告)日：2012-06-20
申请号：EP11152808.9
申请日：2004-09-20
申请人： Enzo Therapeutics, Inc. a fully owned subsidiary of Enzo Biochem, Inc.
发明人： Ilan, Yaron , Margalit, Maya , Elinav, Eran
IPC分类号： A61K39/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/515 , C07K16/28 , C12N5/0636
摘要： The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell. The invention further provides for an ex vivo educated NKT cell and uses thereof in the treatment of immune-related or immune-mediated disorders.

4. 发明公开

EP2465528A3 Educated NKT cells and their uses in the treatment of immune-related disorders. 审中-公开
标题翻译：受过教育的NKT细胞及其在治疗免疫相关疾病中的用途。
公开(公告)号：EP2465528A3
公开(公告)日：2012-09-05
申请号：EP11152811.3
申请日：2004-09-20
申请人： Enzo Therapeutics, Inc. a fully owned subsidiary of Enzo Biochem, Inc.
发明人： Ilan, Yaron , Margalit, Maya , Elinav, Eran
IPC分类号： A61K39/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/515 , C07K16/28 , C12N5/0636
摘要： The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell. The invention further provides for an ex vivo educated NKT cell and uses thereof in the treatment of immune-related or immune-mediated disorders.
摘要翻译：本发明涉及用于治疗需要这种治疗的哺乳动物受试者中的免疫相关或免疫介导的病症的方法。该方法包括通过合适的手段操纵所述受试者中的NKT细胞群的步骤，所述NKT细胞群的操作导致Th1 / Th2平衡向抗炎细胞因子产生细胞的调节。 NKT细胞群的操作可以通过用合适的手段消除所述细胞或者通过离体培养NKT细胞来进行，使得受过教育的NKT细胞具有调节Th1 / Th2平衡以抗炎的能力细胞因子产生细胞。本发明进一步涉及用于治疗哺乳动物受试者中免疫相关或免疫介导的病症的药物组合物。这些组合物包含离体培养的NKT细胞作为有效成分。本发明进一步提供了离体培养的NKT细胞及其在治疗免疫相关或免疫介导的病症中的用途。

5. 发明公开

EP2465529A2 Educated NKT cells and their uses in the treatment of immune-related disorders. 审中-公开
标题翻译： Gebildete NKT-Zellen und deren Verwendung bei der Behandlung von immunbedingtenStörungen
公开(公告)号：EP2465529A2
公开(公告)日：2012-06-20
申请号：EP11152812.1
申请日：2004-09-20
申请人： Enzo Therapeutics, Inc. a fully owned subsidiary of Enzo Biochem, Inc.
发明人： Ilan, Yaron , Margalit, Maya , Elinav, Eran
IPC分类号： A61K39/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/515 , C07K16/28 , C12N5/0636
摘要： The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell. The invention further provides for an ex vivo educated NKT cell and uses thereof in the treatment of immune-related or immune-mediated disorders.
摘要翻译：本发明涉及在需要这种治疗的哺乳动物受试者中治疗免疫相关或免疫介导的疾病的方法。该方法包括通过合适的手段操纵所述受试者中的NKT细胞群的步骤，所述NKT细胞群的操作导致Th1 / Th2平衡向抗炎细胞因子产生细胞的调节。 NKT细胞群的操作可以通过用合适的方法消耗所述细胞或者通过离体培养NKT细胞进行，使得受过教育的NKT细胞具有调节Th1 / Th2平衡以抗炎的能力细胞因子产生细胞。本发明还涉及用于在哺乳动物受试者中治疗免疫相关或免疫介导的病症的药物组合物。这些组合物包含离体受过教育的NKT细胞作为有效成分。本发明进一步提供离体受过教育的NKT细胞及其在治疗免疫相关或免疫介导的疾病中的用途。

6. 发明公开

EP2465526A2 Educated NKT cells and their uses in the treatment of immune-related disorders. 审中-公开
公开(公告)号：EP2465526A2
公开(公告)日：2012-06-20
申请号：EP11152809.7
申请日：2004-09-20
申请人： Enzo Therapeutics, Inc. a fully owned subsidiary of Enzo Biochem, Inc.
发明人： Ilan, Yaron , Margalit, Maya , Elinav, Eran
IPC分类号： A61K39/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/515 , C07K16/28 , C12N5/0636
摘要： The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell. The invention further provides for an ex vivo educated NKT cell and uses thereof in the treatment of immune-related or immune-mediated disorders.

7. 发明授权

EP1452181B1 Regulation of immune responses by manipulation of intermediary metabolite levels 有权
标题翻译：由Zwischenmetabolitgehaltes的操纵手段的免疫应答的调节
公开(公告)号：EP1452181B1
公开(公告)日：2016-04-13
申请号：EP04004583.3
申请日：2004-02-27
申请人： ENZO THERAPEUTICS, INC.
发明人： IIan, Yaron , Engelhardt, Dean L. , Zimran, Ari , Margalit, Maya , Rabbani, Elazar
IPC分类号： A61K31/7032 , A61K35/12 , A61K38/17 , A61P35/00 , A61P31/00 , A61P37/02 , A61K31/00 , A61K38/00 , A61K31/7004 , A61K31/7028 , A61K35/15 , A61K35/17
CPC分类号： A61K31/7032 , A61K9/0019 , A61K9/0053 , A61K31/00 , A61K31/7004 , A61K31/7028 , A61K35/15 , A61K35/17 , A61K38/00
摘要： The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.

8. 发明公开

EP2465528A2 Educated NKT cells and their uses in the treatment of immune-related disorders. 审中-公开
公开(公告)号：EP2465528A2
公开(公告)日：2012-06-20
申请号：EP11152811.3
申请日：2004-09-20
申请人： Enzo Therapeutics, Inc. a fully owned subsidiary of Enzo Biochem, Inc.
发明人： Ilan, Yaron , Margalit, Maya , Elinav, Eran
IPC分类号： A61K39/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/515 , C07K16/28 , C12N5/0636
摘要： The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell. The invention further provides for an ex vivo educated NKT cell and uses thereof in the treatment of immune-related or immune-mediated disorders.

9. 发明公开

EP2465527A2 Educated NKT cells and their uses in the treatment of immune-related disorders. 审中-公开
公开(公告)号：EP2465527A2
公开(公告)日：2012-06-20
申请号：EP11152810.5
申请日：2004-09-20
申请人： Enzo Therapeutics, Inc. a fully owned subsidiary of Enzo Biochem, Inc.
发明人： Ilan, Yaron , Margalit, Maya , Elinav, Eran
IPC分类号： A61K39/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/515 , C07K16/28 , C12N5/0636
摘要： The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell. The invention further provides for an ex vivo educated NKT cell and uses thereof in the treatment of immune-related or immune-mediated disorders.

10. 发明公开

EP2465526A3 Educated NKT cells and their uses in the treatment of immune-related disorders. 审中-公开
公开(公告)号：EP2465526A3
公开(公告)日：2012-08-29
申请号：EP11152809.7
申请日：2004-09-20
申请人： Enzo Therapeutics, Inc. a fully owned subsidiary of Enzo Biochem, Inc.
发明人： Ilan, Yaron , Margalit, Maya , Elinav, Eran
IPC分类号： A61K39/00 , A61K39/395 , C12N5/0783 , A61K35/12 , A61K35/407
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/515 , C07K16/28 , C12N5/0636
摘要： The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell. The invention further provides for an ex vivo educated NKT cell and uses thereof in the treatment of immune-related or immune-mediated disorders.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式